Conclusions: GCAP is recommended as a potential therapeutic option for severe alcoholic hepatitis.

Both antibodies also stained MBs in human liver with alcoholic hepatitis.

Therefore, dual therapy might be considered in treatment of patients with severe alcoholic hepatitis.

We aimed to identify those patients who respond to corticosteroid therapy for alcoholic hepatitis.

Abstinence, corticosteroids, and enteral nutrition remain the cornerstones in the treatment of alcoholic hepatitis.

Methods: We searched PubMed for randomized controlled trials of pharmacologic therapy for severe alcoholic hepatitis.

Furthermore, more severe veno-occlusive lesions were noted in severe alcoholic hepatitis, compared with alcoholic liver cirrhosis.

Three hundred and fifty-two patients with alcoholic hepatitis were evaluated for protein-calorie malnutrition (PCM).

These findings were recognized in the majority of severe alcoholic hepatitis cases and alcoholic liver cirrhosis cases.

Introduction: There is little consensus on the management of alcoholic hepatitis, particularly with regard to corticosteroid therapy.

Severe alcoholic hepatitis (AH) is an acute and often devastating form of alcohol-associated liver disease.

Gut microbial translocation contributes to alcoholic hepatitis.

Background: The prognosis of severe alcoholic hepatitis is poor, and there is no established method for a cure.

Conclusions: Monocyte oxidative burst and bacterial killing is impaired in alcoholic hepatitis while bacterial uptake by phagocytosis is preserved.

Additional studies are needed to establish the beneficial role for vigorous protein-calorie nutritional therapy in the management of alcoholic hepatitis.

Alcohol abuse is a leading cause of liver disease characterized by liver inflammation, fatty liver, alcoholic hepatitis, or liver cirrhosis.